HC Wainwright & Co. Maintains Buy on Protara Therapeutics, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein maintains a Buy rating on Protara Therapeutics (NASDAQ:TARA) with a $23 price target.

April 08, 2024 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Protara Therapeutics with a $23 price target.
The reiteration of a Buy rating and a $23 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards Protara Therapeutics. This endorsement reaffirms the firm's confidence in the company's potential, likely encouraging both current and potential investors about TARA's future prospects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100